Results 21 to 30 of about 195,293 (269)

Strategies to reduce line infections in a small child with homozygous familial hypercholesterolaemia who cannot yet receive LDL apheresis. [PDF]

BMJ Case Rep, 2017
Lee M, Barr J, Kribs S, Filler G.
europepmc   +3 more sources

Outpatient monthly plasmapheresis with post-PLEX evinacumab in pediatric homozygous familial hypercholesterolemia: a case report on port access and immunoglobulin preservation [PDF]

Frontiers in Pediatrics
Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein (LDL) cholesterol levels, predisposing patients to early cardiovascular disease.
Guido Filler, Kambiz Norozi, Kambiz Norozi   +2 more
doaj   +2 more sources

Real-World Safety Data From the World Apheresis Association Registry for the Spectra Optia Apheresis System. [PDF]

J Clin Apher
ABSTRACT In this study we analyzed 12 years of adverse events, (AE) data from the World Apheresis Association, (WAA) Registry specific to the Spectra Optia Apheresis System. We queried WAA Registry data, (2012–2023) on apheresis procedures performed exclusively on the Spectra Optia Apheresis System.
Haubner A, Mendoza S, Vrielink H, Witt V, Deeren D, Bojanic I, Gasova Z, Aandahl A, Glatt TN, Vasilache AM, Newman E, Strineholm V, Skosana Y, Stegmayr B.   +13 more
europepmc   +2 more sources

Updated evidence of beneficial effect of LDL apheresis for refractory nephrotic syndrome due to a variety of causative diseases for nationwide and global approval

Therapeutic apheresis and dialysis, 2023
Low‐density lipoprotein apheresis (LDL‐A) therapy has shown reasonable efficacy in treating nephrotic syndrome (NS) refractory to initial drug therapy and has been covered by National Health Insurance for the indication of drug‐resistant focal segmental ...
E. Muso, H. Kakita, Hiroyuki Suzuki, T. Tsukamoto   +3 more
semanticscholar   +1 more source

New approaches in detection and treatment of familial hypercholesterolemia [PDF]

, 2015
Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder that clinically leads to increased low density lipoprotein-cholesterol (LDL-C) levels. As a consequence, FH patients are at high risk for cardiovascular disease (CVD). Mutations
Hartgers, ML, Hovingh, GK, Ray, KK
core   +12 more sources

LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: A retrospective analysis [PDF]

Diabetes Research and Clinical Practice, 2014
Eiichi Sato, Mayuko Amaha, Mayumi Nomura, Daisuke Matsumura, Yoshihiko Ueda, Tsukasa Nakamura   +5 more
openalex   +2 more sources

SARS-CoV-2 IgG spike protein antibody response in mRNA-1273 Moderna® vaccinated patients on maintenance immunoapheresis – a cohort study

Frontiers in Immunology, 2022
BackgroundThe SARS-CoV-2 pandemic increased mortality and morbidity among immunocompromised populations. Vaccination is the most important preventive measure, however, its effectiveness among patients depending on maintenance immunoglobulin G (IgG ...
Martina Gaggl, Constantin Aschauer, Christof Aigner, Gregor Bond, Andreas Vychytil, Robert Strassl, Ludwig Wagner, Gere Sunder-Plassmann, Alice Schmidt   +8 more
doaj   +1 more source

Just not cosmesis! Role of low-density lipoprotein apheresis in familial hypercholesterolemia: Experience at a newly developed tertiary care institution in Northern India

Asian Journal of Transfusion Science, 2021
Familial hypercholesterolemia (FH) is characterized by an increase in plasma low-density lipoprotein-cholesterol (LDL-C) levels. It presents with tendon/skin xanthomas and premature atherosclerotic cardiovascular disease.
Daljit Kaur, Gita Negi, Rohit Walia, Sheetal Malhotra, Riti Bhatia, Sushant K Meinia, Saikat Mandal, Ashish Jain   +7 more
doaj   +1 more source

Rheocarna treatment for non-dialysis patients. [PDF]

Ther Apher Dial
Abstract Introduction Rheocarna has attracted attention as an alternative therapy for severe chronic limb‐threatening ischemia, and there have been reports of its usefulness. However, most of these reports have been on dialysis patients, and there are few reports on the treatment conditions and efficacy in non‐dialysis patients.
Ohkubo A, Sakurasawa T, Hoshikawa Y, Deushi M, Usui M, Komori S, Itagaki A, Yamamoto H, Seshima H, Kurashima N, Iimori S, Naito S.   +11 more
europepmc   +2 more sources

Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. [PDF]

Clin Exp Nephrol, 2014
LDL-apheresis is a method to correct dyslipidemia rapidly. It is expected to alleviate the tissue toxicity of persistent dyslipidemia in not only primary, but also in secondary dyslipidemia associated with refractory nephrotic syndrome, and to have a ...
Muso E.
europepmc   +2 more sources